at Zacks.com (Jan 13, 2015)
Bayer (BAYRY.PK -2%) and Regeneron (REGN -1%) lose their U.K. patent fight on Eylea, a potential blockbuster VEGF Tarp-Eye treatment produced jointly by the two companies. A London Court has ruled that the drug infringes a patent held by Roche (RHHBY.PK -1.4%) subsidiary Genentech.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 2, 2015)
at Zacks.com (Dec 29, 2014)
at Zacks.com (Dec 23, 2014)
at Zacks.com (Dec 19, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs